Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00825058 |
Recruitment Status :
Completed
First Posted : January 19, 2009
Last Update Posted : March 25, 2009
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Primary objective :
- To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode.
Secondary objectives:
- To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Major Depressive Disorders | Drug: amibegron (SR58611A) Drug: placebo Drug: paroxetine | Phase 3 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 317 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | Double (Participant, Investigator) |
Primary Purpose: | Treatment |
Official Title: | A Double-Blind, Multicenter Study Evaluating the Efficacy and Safety of One Fixed Dose of SR58611A (700 mg/Day) Versus Placebo and Paroxetine (20 mg/Day) in Patients With a Recurrent Major Depressive Episode. |
Study Start Date : | November 2003 |
Actual Primary Completion Date : | May 2004 |
Actual Study Completion Date : | October 2004 |

Arm | Intervention/treatment |
---|---|
Experimental: 1 |
Drug: amibegron (SR58611A)
oral administration 2 X 350mg/day at 12 hours intervals |
Placebo Comparator: 2 |
Drug: placebo
oral administration 12 hours intervals |
Active Comparator: 3 |
Drug: paroxetine
oral 20 mg/day |
- change from baseline of the total score of the HAM-D 17 items. [ Time Frame: 6 weeks ]
- HAM-D subscores [ Time Frame: 6 weeks ]
- HAM-D responders and remitters [ Time Frame: 6 weeks ]
- HAM-A total score and subscores [ Time Frame: 6 weeks ]
- MADRS total score [ Time Frame: 6 weeks ]
- clinical global impression (CGI) severity and improvement scores [ Time Frame: 6 weeks ]
- patient global impression (PGI) improvement score [ Time Frame: 6 weeks ]
- social and occupational functioning assessment scale (SOFAS) score [ Time Frame: 6 weeks ]
- clinical monitoring of adverse events (AEs) [ Time Frame: 6 weeks ]
- laboratory parameters [ Time Frame: 6 weeks ]
- electrocardiogram (ECG) parameters, change in vital signs and body weight [ Time Frame: 6 weeks ]

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- patients suffering from a recurrent major depressive episode of at least moderate intensity (DSM-IV)
- patients have been hospitalized for the treatment of a previous episode, or a previous episode required antidepressant treatment(s)at the recommended dose level for at least 2 months.
- the duration of the current episode is of at least six weeks unless the severity of symptoms justifies shorter duration

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00825058
Bulgaria | |
Sanofi-Aventis Administrative Office | |
Sofia, Bulgaria | |
Croatia | |
Sanofi-Aventis Administrative Office | |
Zagreb, Croatia | |
Czech Republic | |
Sanofi-Aventis Administrative Office | |
Praha, Czech Republic | |
Estonia | |
Sanofi-Aventis Administrative Office | |
Tallinn, Estonia | |
France | |
Sanofi-Aventis Administrative Office | |
Paris, France | |
Montenegro | |
Sanofi-Aventis Administrative Office | |
Montenegro, Montenegro | |
Netherlands | |
Sanofi-Aventis Administrative Office | |
Gouda, Netherlands | |
Serbia | |
Sanofi-Aventis Administrative Office | |
Belgrade, Serbia |
Study Director: | ICD CSD | Sanofi |
Responsible Party: | ICD Study Director, sanofi-aventis |
ClinicalTrials.gov Identifier: | NCT00825058 |
Other Study ID Numbers: |
EFC5374 |
First Posted: | January 19, 2009 Key Record Dates |
Last Update Posted: | March 25, 2009 |
Last Verified: | March 2009 |
Depression |
Depressive Disorder Depressive Disorder, Major Mood Disorders Mental Disorders Paroxetine Amibegron Serotonin Uptake Inhibitors Neurotransmitter Uptake Inhibitors Membrane Transport Modulators Molecular Mechanisms of Pharmacological Action Neurotransmitter Agents |
Serotonin Agents Physiological Effects of Drugs Antidepressive Agents, Second-Generation Antidepressive Agents Psychotropic Drugs Cytochrome P-450 CYP2D6 Inhibitors Cytochrome P-450 Enzyme Inhibitors Enzyme Inhibitors Adrenergic beta-Agonists Adrenergic Agonists Adrenergic Agents |